Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm Programs
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Total Metals Acquires 100% Interest in the High-Grade Pick Lake Critical Minerals Property from Frontier Energy Limited
Generation Uranium Defines Multiple High-Impact Drill Targets At Yath Project, Leveraging Proven Discovery Model In One of Canada's Hottest Uranium Districts
SAGA Metals Executes Title Transfer Agreement to Expand Wolverine Heavy Rare Earth Element Project in Labrador-Grab Sample Assays Included up to 21.6% TREO
